Enliven Therapeutics Reports Promising 44% MMR Rate at 24 Weeks in Phase 1 CML Trial for ELVN-001

Reported cumulative MMR rate of 44% by 24 weeks, with stable or deepening responses between weeks 12 and 24, continuing to surpass prior Phase 1 trials o...

September 30, 2024 | Monday | News
Takara Bio Europe Launches Shasta™ Single-Cell System, Advancing High-Throughput Oncology Biomarker Discovery

Takara Bio Europe, a wholly owned subsidiary of Takara Bio Inc., announces the launch of the Shasta™ Single-Cell System at the 2024 Human Cell A...

September 27, 2024 | Friday | News
Thermo Fisher Scientific Expands OSD Capabilities with $22 Million Investment to Accelerate Drug Development

To provide flexible and innovative solutions for early development challenges commonly faced by biotech and pharmaceutical companies, Thermo Fisher Scien...

September 27, 2024 | Friday | News
Emmes Secures Major NIH Contract to Lead Clinical Coordinating Center for National Institute on Drug Abuse Trials

Emmes, part of Emmes Group, announced they will provide a Clinical Coordinating Center for the NIH's National Institute on Drug Abuse Clinical Trials &nbs...

September 26, 2024 | Thursday | News
Eli Lilly CEO David Ricks Announces Major Expansion of India Research Hub, Poised to Transform Global Drug Innovation

Eli Lilly and Company (NYSE: LLY), a global leader in biopharmaceuticals, has announced plans to expand its research and development (R&D) center in ...

September 24, 2024 | Tuesday | News
Nxera Pharma Secures Japanese Approval for QUVIVIQ™ to Treat Insomnia Based on Positive Phase 3 Trial Results

The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3...

September 24, 2024 | Tuesday | News
Thermo Fisher's PPD Clinical Research Expands to GoCo Health Innovation City in Sweden

The PPD clinical research business joins GoCo Health Innovation City in Gothenburg, Sweden The PPD™ clinical research business of Thermo Fisher Sc...

September 19, 2024 | Thursday | News
Vidac Pharma Secures Broad U.S. Patent for Pioneering Cancer Treatment Mode of Action

Vidac Pharma Holdings Plc., a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments,  announces that the U...

September 19, 2024 | Thursday | News
BeiGene Secures Israeli Ministry of Health Approval for TEVIMBRA® in Treating Esophageal Squamous Cell Carcinoma

BeiGene, a global oncology company, announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA® (tislelizumab) as monotherapy for t...

September 18, 2024 | Wednesday | News
Immutep Presents Promising Phase IIb Trial Results of Efti and KEYTRUDA® at ESMO 2024

Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 In patients with any PD-L1 expression (CPS ≥1), efti in co...

September 17, 2024 | Tuesday | News
MaxCyte and Kamau Therapeutics Partner to Advance Next-Gen Gene Therapies for Sickle Cell Disease

MaxCyte, Inc.,  a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and comme...

September 16, 2024 | Monday | News
CPC Introduces Innovative Aseptic Micro-Connector for Cell and Gene Therapy Freeze Cassettes

CPC (Colder Products Company), part of Dover  and a leading manufacturer of connection technologies used in biopharmaceutical processing, today...

September 12, 2024 | Thursday | News
Symbiosis Pharmaceutical Expands Manufacturing Capacity with New Facility in Stirling

Symbiosis Pharmaceutical Services Ltd (Symbiosis), a rapidly growing sterile biopharmaceutical Contract Manufacturing Organisation (CMO) announces the pu...

September 09, 2024 | Monday | News
Scantox Group Acquires UK-Based Gentronix to Expand Genetic Toxicology Services

Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Resear...

September 09, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close